Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Bladder Cancer Molecular Therapy

  • Hwa-Chain Robert Wang
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_7105-8

Synonyms

Definition

Therapy targeting molecular pathways that are aberrantly-regulated in cancer cells to: (i) increase apoptotic signals, (ii) decrease survival signals, and (iii) reduce drug-resistant signals.

Characteristics

Molecular Therapy

Molecular therapy enhances or suppresses molecular pathways that are aberrantly-regulated in cancer cells to: (i) increase apoptotic signals, (ii) decrease survival signals, and (iii) reduce drug-resistant signals. These processes induce selective death of cancerous cells, leaving noncancerous cells intact. Currently, some therapeutic strategies for treating urothelial carcinomas (UCs) emphasize targeted inhibition of aberrantly-regulated signaling modulators in order to abrogate cancer-associated alterations. However, considering these signaling modulators are required for regulation of cellular activities in both normal and cancer cells, inhibition of these modulators in cancer cells may also induce...

Keywords

Reactive Oxygen Species Mutational Activation Molecular Therapy Reactive Oxygen Species Elevation Urinary Bladder Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Ballatori N, Krance SM, Notenboom S, Shi S, Tieu K, Hammond CL (2009) Glutathione dysregulation and the etiology and progression of human diseases. Biol Chem 39:191–214Google Scholar
  2. Cagnol S, Chambard JC (2010) ERK and cell death: mechanisms of ERK-induced cell death – apoptosis, autophagy and senescence. FEBS J 277:2–21CrossRefPubMedGoogle Scholar
  3. Hait WN, Hambley TW (2009) Targeted cancer therapeutics. Cancer Res 69:1263–1267CrossRefPubMedGoogle Scholar
  4. Wagner JM, Hackanson B, Lübbert M, Jung M (2010) Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenetics 1:117–136CrossRefPubMedPubMedCentralGoogle Scholar
  5. Wang HC, Choudhary S (2011) Reactive oxygen species-mediated therapeutic control of bladder cancer. Nat Rev Urol 8:608–616CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Molecular Oncology, Department of Biomedical and Diagnostic SciencesThe University of Tennessee, College of Veterinary MedicineKnoxvilleUSA